GSK_Annual_Report_2021

Annual Report 2020-21 39 Registrations were successfully completed for (i) a new fixed dose combination of Fluticasone Furoate, Umeclidinium and Vilanterol Powder for Inhalation (Trelegy) for chronic obstructive pulmonary disease (COPD); (ii) new strength of an already marketed oral suspension of Augmentin viz. Amoxycillin and Potassium Clavulanate oral suspension 642.9 mg/5ml (Augmentin ES) ; and (iii) a ready-to-use liquid formulation of Mepolizumab Injection 100mg (Nucala) for treatment of severe refractory eosinophilic asthma in adults. These approvals will enable timely access to new and innovative therapeutic options to patients in India, besides improving compliance to treatment of existing products with new formulations and strength. (e) Medical affairs and medical governance Despite challenges associated with the pandemic during the year, your Company’s medical team maintained its robust connect with the healthcare community, to keep them updated on the science of disease and the Company’s products. The team delivered over 2,200 scientific presentations through virtual GSK standalone scientific promotional meetings (SPMs) and webcasts, reaching over 90,000 HCPs. In addition, your Company’s medical affairs team ensured continued one-to-one interactions with HCPs, by utilising an optimal mix of digital platforms and delivering over 3,300 interactions. Full support was provided to the healthcare community in the fight against COVID-19 through webinars with experts across specialties on effective diagnosis and management of the coronavirus, in addition to various aspects of telemedicine. These initiatives have helped your Company build greater trust and credibility as a science-led organisation, focused on benefitting patients. In the Anti-Infective therapy area, your Company’s medical team delivered over 1,200 scientific presentations, reaching over 30,000 HCPs, and more than 1,500 one-to-one interactions with experts across specialties. In Dermatology, the medical team continued its efforts to drive appropriate use of topical steroids and dissemination of science behind relevant disease areas through more than 900 scientific presentations. The medical team responsible for Primary Care contributed by delivering over 220 scientific presentations, reaching over 30,000 HCPs, and more than 300 one-to-one interactions with experts, including endocrinologists. In the Respiratory therapy area, your Company’s medical experts participated in over 100 promotional meetings as speakers and moderators, reaching approximately 1,900 HCPs, in addition to more than 1,300 one-to- one scientific interactions with external experts. The medical science liaisons (MSLs) led six non-promotional meetings on severe asthma and conducted an advisory board meeting to gather insights on the role of eosinophils in health and disease. The medical team initiated the Nucala Home Administration programme in 2020, to support eligible patients to continue treatment amid the pandemic challenges. The team also launched the Severe Asthma Clinic programme to support HCPs in early diagnosis and phenotyping of patients of the disease. Several key evidence generation activities, such as two Investigator Sponsored Studies (ISS) and eight key review articles published in peer-reviewed indexed medical journals, were undertaken to spread vaccine awareness. The medical team delivered 390 scientific presentations and 860 one-to-one scientific interactions, reaching out to more than 23,000 doctors. The vaccines medical team also collaborated with the Indian Medical Association (IMA) to support the module development of the Life Course Immunisation Guidebook and its rollout to their members. (f) Internal control framework Your Company conducts its business with integrity and high standards of ethical behaviour, and in compliance with the laws and regulations that govern the business. Its Internal Control Framework (ICF) is a comprehensive enterprise- wide risk management model and supports the continuous process of identification, evaluation and management of the Company’s risks. ICF is supported by standard operating procedures, policies and guidelines, including suitable monitoring procedures and self-assessment exercises. Compliance with laws and regulations is monitored through a well-crafted framework. As required by the Companies Act 2013, your